Overexpression of Rab25 contributes to metastasis of bladder cancer through induction of epithelial–mesenchymal transition and activation of Akt/GSK-3β/Snail signaling
出版年份 2013 全文链接
标题
Overexpression of Rab25 contributes to metastasis of bladder cancer through induction of epithelial–mesenchymal transition and activation of Akt/GSK-3β/Snail signaling
作者
关键词
-
出版物
CARCINOGENESIS
Volume 34, Issue 10, Pages 2401-2408
出版商
Oxford University Press (OUP)
发表日期
2013-05-31
DOI
10.1093/carcin/bgt187
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway
- (2012) S Maseki et al. BRITISH JOURNAL OF CANCER
- Rab25 Is a Tumor Suppressor Gene with Antiangiogenic and Anti-Invasive Activities in Esophageal Squamous Cell Carcinoma
- (2012) M. Tong et al. CANCER RESEARCH
- BMK1 Kinase Suppresses Epithelial-Mesenchymal Transition through the Akt/GSK3 Signaling Pathway
- (2012) R. Chen et al. CANCER RESEARCH
- Cyclin G1-mediated epithelial-mesenchymal transition via phosphoinositide 3-kinase/Akt signaling facilitates liver cancer progression
- (2012) Wen Wen et al. HEPATOLOGY
- Leptin-induced Epithelial-Mesenchymal Transition in Breast Cancer Cells Requires β-Catenin Activation via Akt/GSK3- and MTA1/Wnt1 Protein-dependent Pathways
- (2012) Dan Yan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells
- (2012) Toni Celià-Terrassa et al. JOURNAL OF CLINICAL INVESTIGATION
- Increased expression of Rab25 in breast cancer correlates with lymphatic metastasis
- (2012) Y. X. Yin et al. TUMOR BIOLOGY
- Sam68 expression and cytoplasmic localization is correlated with lymph node metastasis as well as prognosis in patients with early-stage cervical cancer
- (2011) Z. Li et al. ANNALS OF ONCOLOGY
- Rab25 and CLIC3 Collaborate to Promote Integrin Recycling from Late Endosomes/Lysosomes and Drive Cancer Progression
- (2011) Marta A. Dozynkiewicz et al. DEVELOPMENTAL CELL
- The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2
- (2011) Fang Zheng et al. GUT
- Twisted Epithelial-to-Mesenchymal Transition Promotes Progression of Surviving Bladder Cancer T24 Cells with hTERT-Dysfunction
- (2011) Yan Xue et al. PLoS One
- Rab25 as a tumour suppressor in colon carcinogenesis
- (2010) J R Goldenring et al. BRITISH JOURNAL OF CANCER
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Loss of Rab25 promotes the development of intestinal neoplasia in mice and is associated with human colorectal adenocarcinomas
- (2010) Ki Taek Nam et al. JOURNAL OF CLINICAL INVESTIGATION
- Epstein-Barr Virus-Encoded LMP2A Induces an Epithelial–Mesenchymal Transition and Increases the Number of Side Population Stem-like Cancer Cells in Nasopharyngeal Carcinoma
- (2010) Qing-Li Kong et al. PLoS Pathogens
- Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer
- (2009) David J. McConkey et al. CANCER AND METASTASIS REVIEWS
- The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells
- (2009) Li-Bing Song et al. JOURNAL OF CLINICAL INVESTIGATION
- The Emerging Role of the RAB25 Small GTPase in Cancer
- (2009) Roshan Agarwal et al. TRAFFIC
- Snail expression is an independent predictor of tumor recurrence in superficial bladder cancers
- (2009) Franck Bruyere et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Molecular biomarkers in urothelial bladder cancer
- (2008) Wun-Jae Kim et al. CANCER SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started